MDM2 and neoplasm: Our study uncovers that in p53 WT condition MDM2 inhibitor acts through suppressing the novel p53 → E2F → PEG10 pathway, on the other hand in p53 mutant condition it alters EMT signaling leading to reduced tumor invasiveness.